Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI).
Dörner T, Schulze-Koops H, Burmester GR, Iking-Konert C, Schmalzing M, Engel A, Kästner P, Kellner H, Kurthen R, Krüger K, Rubbert-Roth A, Schwenke H, Peters MA, Tony HP. Dörner T, et al. Clin Exp Rheumatol. 2019 Nov-Dec;37(6):937-945. Epub 2019 Apr 16. Clin Exp Rheumatol. 2019. PMID: 31025930 Free article. Clinical Trial.
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry.
Ciurea A, Götschi A, Bräm R, Bürki K, Exer P, Andor M, Nissen MJ, Möller B, Hügle T, Rubbert-Roth A, Kyburz D, Distler O, Scherer A, Micheroli R. Ciurea A, et al. Among authors: rubbert roth a. RMD Open. 2023 Dec 1;9(4):e003455. doi: 10.1136/rmdopen-2023-003455. RMD Open. 2023. PMID: 38053462 Free PMC article.
Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR).
Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreño L, Armstrong G, Collinson N, Shaw TM; MIRROR Trial Investigators. Rubbert-Roth A, et al. Rheumatology (Oxford). 2010 Sep;49(9):1683-93. doi: 10.1093/rheumatology/keq116. Epub 2010 May 12. Rheumatology (Oxford). 2010. PMID: 20463186 Free PMC article. Clinical Trial.
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).
Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kötter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Müller-Ladner U, König R, Fiehn C, Burgwinkel P, Budde K, Sörensen H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier FM, Hunzelmann N, Schmidt E, Bergner R, Schwarting A, Eming R, Hertl M, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog AL, Wiendl H, Jakob W, Schmidt E, Freivogel K, Dörner T; GRAID investigators. Tony HP, et al. Arthritis Res Ther. 2011 May 13;13(3):R75. doi: 10.1186/ar3337. Arthritis Res Ther. 2011. PMID: 21569519 Free PMC article.
129 results